Bioline RX Ltd. is a biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. The Company's portfolio consists of clinical stage candidates including BL-1020 for schizophrenia , BL-1040, for treatment of patients following a myocardial infarction, BL-5010 for non-surgical removal of skin lesions, BL-1021 for neuropathic pain and BL-7040 for treating Inflammatory Bowel Disease. In addition, BioLineRx has many products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, oncology, infectious diseases, cardiovascular and autoimmune diseases.
| Revenue (Most Recent Fiscal Year) | $28.94M |
| Net Income (Most Recent Fiscal Year) | $-9.22M |
| PE Ratio (Current Year Earnings Estimate) | 47.39 |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 0.56 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 0.60 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -15.21% |
| Net Margin (Trailing 12 Months) | -15.21% |
| Return on Equity (Trailing 12 Months) | -23.93% |
| Return on Assets (Trailing 12 Months) | -6.80% |
| Current Ratio (Most Recent Fiscal Quarter) | 2.27 |
| Quick Ratio (Most Recent Fiscal Quarter) | 1.56 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.37 |
| Inventory Turnover (Trailing 12 Months) | 2.30 |
| Book Value per Share (Most Recent Fiscal Quarter) | $6.27 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.39 |
| Earnings per Share (Most Recent Fiscal Year) | $-6.00 |
| Diluted Earnings per Share (Trailing 12 Months) | -- |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 3.33M |
| Free Float | 3.29M |
| Market Capitalization | $12.62M |
| Average Volume (Last 20 Days) | 0.03M |
| Beta (Past 60 Months) | 1.15 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 1.10% |
| Percentage Held By Institutions (Latest 13F Reports) | 1.56% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |